Dr. Christopher L. Reading This is Me

Education

 View all 127 references Web References

1. 1. Hollis-Eden Pharmaceuticals — Richard Hollis

   dev.holliseden.com/content/?pa - [Cached]

   Published on: 8/4/2008   Last Visited: 8/4/2008

   CHRISTOPHER READING

2. 2. www.sec.gov

   www.sec.gov/Archives/edgar/dat - [Cached]

   Published on: 4/25/2008   Last Visited: 4/26/2008

   Christopher L. Reading, Ph.D.
   ...
   Christopher L. Reading, Ph.D., became Vice President of Scientific Development in 1999.Dr. Reading was promoted to Executive Vice President, Scientific Development in 2002 and to Chief Scientific Officer in February 2008.Prior to joining Hollis-Eden, Dr. Reading was Vice President of Product and Process Development at Novartis Inc.-owned SyStemix Inc.During this time, he successfully filed three investigational new drug applications (INDs) in the areas of stem cell therapy technology and stem cell gene therapy for HIV/AIDS.Prior to joining SyStemix, Dr. Reading served on the faculty of the M.D.Anderson Cancer Center in Houston for nearly 13 years.His positions there included Associate and Assistant Professor of Medicine in the Departments of Hematology and Tumor Biology.During his career, Dr. Reading has given more than 25 national and international scientific presentations, published more than 50 peer-reviewed journal articles and 15 invited journal articles as well as written nearly 20 book chapters, and received numerous grants and contracts which supported his research activities.Dr. Reading has served on the National Science Foundation Advisory Committee for Small Business Innovative Research Grants (SBIR) as well as on the editorial boards of Journal of Biological Response Modifiers and Molecular Biotherapy.He holds a number of patents for his work with monoclonal antibodies and devices.Dr. Reading received his Ph.D. in Biochemistry at the University of California at Berkeley and completed postdoctoral study in tumor biology at The University of California at Irvine.He earned his B.A. in biology at the University of California at San Diego.

3. 3. Hollis-Eden Pharmaceuticals — Christopher Reading

   dev.holliseden.com/content/?pa - [Cached]

   Published on: 8/4/2008   Last Visited: 8/4/2008

   CHRISTOPHER READINGHollis-Eden Pharmaceuticals - Christopher Reading
   ...
   CHRISTOPHER READING
   ...
   > Christopher Reading
   ...
   Christopher L. Reading, Ph.D. Chief Scientific Officer
   
   Christopher L. Reading, Ph.D., became Vice President of Scientific Development in 1999 and was promoted to Executive Vice President, Scientific Development in 2002.Prior to joining Hollis-Eden, Dr. Reading was Vice President of Product and Process Development at Novartis Inc.-owned SyStemix Inc.During this time, he successfully filed three investigational new drug applications (INDs) in the areas of stem cell therapy technology and stem cell gene therapy for HIV/AIDS.Prior to joining SyStemix, Dr. Reading served on the faculty of the M.D.Anderson Cancer Center in Houston for nearly 13 years.His positions there included Associate and Assistant Professor of Medicine in the Departments of Hematology and Tumor Biology.During his career, Dr. Reading has given more than 25 national and international scientific presentations, published more than 50 peer-reviewed journal articles and 15 invited journal articles as well as written nearly 20 book chapters, and received numerous grants and contracts which supported his research activities.Dr. Reading has served on the National Science Foundation Advisory Committee for Small Business Innovative Research Grants (SBIR) as well as on the editorial boards of Journal of Biological Response Modifiers and Molecular Biotherapy.He holds a number of patents for his work with monoclonal antibodies and devices.Dr. Reading received his Ph.D. in Biochemistry at the University of California at Berkeley and completed postdoctoral study in tumor biology at The University of California at Irvine.He earned his B.A. in biology at the University of California at San Diego.